Back to Search
Start Over
Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development – (II) A Randomized Trial with IL‐5 Antagonists.
- Source :
- Clinical Pharmacology & Therapeutics; Jan2023, Vol. 113 Issue 1, p80-89, 10p
- Publication Year :
- 2023
-
Abstract
- The US Food and Drug Administration (FDA) guidance describes how pharmacodynamic (PD) biomarkers can be used to address residual uncertainty and demonstrate no clinically meaningful differences between a proposed biosimilar and its reference product without relying on clinical efficacy end point(s). Pilot studies and modeling can inform dosing for such PD studies. To that end, we conducted a randomized, double‐blinded, placebo‐controlled, single‐dose, parallel‐arm clinical study in healthy participants to evaluate approaches to address information gaps, inform best practices for analysis of biomarker samples and study results, and apply emerging technologies in biomarker characterization. Seventy‐two healthy participants (n = 8 per arm) received either placebo or 1 of 4 doses of the interleukin‐5 inhibitors mepolizumab (3–24 mg) or reslizumab (0.1–0.8 mg/kg). A clinical study using doses lower than approved therapeutic doses was combined with modeling and simulation to evaluate the dose–response relationship of the biomarker eosinophils. There was no dose–response relationship for eosinophil counts due to variability, although the mepolizumab 24 mg and reslizumab 0.8 mg/kg doses showed clear effects. Published indirect‐response models were used to explore eosinophil data across doses from this study and the unstudied therapeutic doses. Simulations were used to calculate typical PD metrics, such as baseline‐adjusted area under the effect curve and maximum change from baseline. The simulation results demonstrate sensitivity of eosinophils as a PD biomarker and indicate doses lower than the approved doses would have PD responses overlapping with variability in the placebo arm. The simulation results further highlight the utility of model‐based approaches in supporting use of PD biomarkers in biosimilar development. [ABSTRACT FROM AUTHOR]
- Subjects :
- TECHNOLOGICAL innovations
BIOMARKERS
BIOSIMILARS
EOSINOPHILS
INTERLEUKIN-5
Subjects
Details
- Language :
- English
- ISSN :
- 00099236
- Volume :
- 113
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Clinical Pharmacology & Therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 160934601
- Full Text :
- https://doi.org/10.1002/cpt.2760